Antidepressants and the brain

Pedro Delgado, Francisco Moreno

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The pathophysiology and effects of antidepressants in the brain are still poorly understood. While it is generally accepted that increasing the levels of monoamine in the brain is an effective way to alleviate depression, the precise neurobiological mechanisms are unclear. The evidence that monoamine function is impaired in individuals with depression is largely indirect. However, the neurotransmitter depletion model allows a more direct investigation of the role of the monoamines. In this model, tryptophan depletion is used to lower levels of serotonin and α-methylparatyrosine is used to induce catecholamine depletion in the brain. Studies have shown that such depletion transiently reverses antidepressant responses in the majority of patients, the response being dependent on the type of antidepressant used. However, depletion in unmedicated patients with depression did not worsen the depressive symptoms, neither did it cause depression in healthy subjects with no history of mental illness. The cause(s) of depression therefore appears to be more complex than simply a reduction in levels of monoamine or diminished function in these systems. The pathophysiology of depression may relate to dysfunction in brain areas modulated by monoamine systems. Antidepressant drugs may mediate their effects by causing adaptive changes in neurones localised in these brain areas.

Original languageEnglish (US)
JournalInternational Clinical Psychopharmacology
Volume14
Issue numberSUPPL. 1
DOIs
StatePublished - 1999

Fingerprint

Antidepressive Agents
Depression
Brain
Tryptophan
Catecholamines
Neurotransmitter Agents
Serotonin
Healthy Volunteers
Neurons

Keywords

  • Alpha-methylparatyrosine
  • Depletion
  • Depression
  • Noradrenaline
  • Serotonin
  • Tryptophan

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antidepressants and the brain. / Delgado, Pedro; Moreno, Francisco.

In: International Clinical Psychopharmacology, Vol. 14, No. SUPPL. 1, 1999.

Research output: Contribution to journalArticle

@article{e268a37340dd435e8d0c9eaa50c28129,
title = "Antidepressants and the brain",
abstract = "The pathophysiology and effects of antidepressants in the brain are still poorly understood. While it is generally accepted that increasing the levels of monoamine in the brain is an effective way to alleviate depression, the precise neurobiological mechanisms are unclear. The evidence that monoamine function is impaired in individuals with depression is largely indirect. However, the neurotransmitter depletion model allows a more direct investigation of the role of the monoamines. In this model, tryptophan depletion is used to lower levels of serotonin and α-methylparatyrosine is used to induce catecholamine depletion in the brain. Studies have shown that such depletion transiently reverses antidepressant responses in the majority of patients, the response being dependent on the type of antidepressant used. However, depletion in unmedicated patients with depression did not worsen the depressive symptoms, neither did it cause depression in healthy subjects with no history of mental illness. The cause(s) of depression therefore appears to be more complex than simply a reduction in levels of monoamine or diminished function in these systems. The pathophysiology of depression may relate to dysfunction in brain areas modulated by monoamine systems. Antidepressant drugs may mediate their effects by causing adaptive changes in neurones localised in these brain areas.",
keywords = "Alpha-methylparatyrosine, Depletion, Depression, Noradrenaline, Serotonin, Tryptophan",
author = "Pedro Delgado and Francisco Moreno",
year = "1999",
doi = "10.1097/00004850-199905001-00003",
language = "English (US)",
volume = "14",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Antidepressants and the brain

AU - Delgado, Pedro

AU - Moreno, Francisco

PY - 1999

Y1 - 1999

N2 - The pathophysiology and effects of antidepressants in the brain are still poorly understood. While it is generally accepted that increasing the levels of monoamine in the brain is an effective way to alleviate depression, the precise neurobiological mechanisms are unclear. The evidence that monoamine function is impaired in individuals with depression is largely indirect. However, the neurotransmitter depletion model allows a more direct investigation of the role of the monoamines. In this model, tryptophan depletion is used to lower levels of serotonin and α-methylparatyrosine is used to induce catecholamine depletion in the brain. Studies have shown that such depletion transiently reverses antidepressant responses in the majority of patients, the response being dependent on the type of antidepressant used. However, depletion in unmedicated patients with depression did not worsen the depressive symptoms, neither did it cause depression in healthy subjects with no history of mental illness. The cause(s) of depression therefore appears to be more complex than simply a reduction in levels of monoamine or diminished function in these systems. The pathophysiology of depression may relate to dysfunction in brain areas modulated by monoamine systems. Antidepressant drugs may mediate their effects by causing adaptive changes in neurones localised in these brain areas.

AB - The pathophysiology and effects of antidepressants in the brain are still poorly understood. While it is generally accepted that increasing the levels of monoamine in the brain is an effective way to alleviate depression, the precise neurobiological mechanisms are unclear. The evidence that monoamine function is impaired in individuals with depression is largely indirect. However, the neurotransmitter depletion model allows a more direct investigation of the role of the monoamines. In this model, tryptophan depletion is used to lower levels of serotonin and α-methylparatyrosine is used to induce catecholamine depletion in the brain. Studies have shown that such depletion transiently reverses antidepressant responses in the majority of patients, the response being dependent on the type of antidepressant used. However, depletion in unmedicated patients with depression did not worsen the depressive symptoms, neither did it cause depression in healthy subjects with no history of mental illness. The cause(s) of depression therefore appears to be more complex than simply a reduction in levels of monoamine or diminished function in these systems. The pathophysiology of depression may relate to dysfunction in brain areas modulated by monoamine systems. Antidepressant drugs may mediate their effects by causing adaptive changes in neurones localised in these brain areas.

KW - Alpha-methylparatyrosine

KW - Depletion

KW - Depression

KW - Noradrenaline

KW - Serotonin

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=0032773369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032773369&partnerID=8YFLogxK

U2 - 10.1097/00004850-199905001-00003

DO - 10.1097/00004850-199905001-00003

M3 - Article

C2 - 10468323

AN - SCOPUS:0032773369

VL - 14

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - SUPPL. 1

ER -